JCR Pharmaceuticals Co., Ltd.
JCR製藥
- Listing
- TSE 4552
- Headquarters
- Hyogo, Japan
Clinical-stage assets
| Asset | Stage at source date | Indication | Source date |
|---|---|---|---|
| JR-141 / pabinafusp alfa / IZCARGO | Global Phase 3; approved in Japan for Hunter syndrome | 2026-10-02 |
Licensing announcements since 2025
| Date | Counterparty | Asset / platform | Upfront | Near-term | Potential total | Stage at announcement |
|---|---|---|---|---|---|---|
| 2026-10-02 | Italfarmaco S.p.A. | JR-141 / pabinafusp alfa / IZCARGO | Global Phase 3; approved in Japan for Hunter syndrome |